Department of Clinical Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Autophagy Research Center, Department of Clinical Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Diabetes Obes Metab. 2024 Oct;26(10):4551-4561. doi: 10.1111/dom.15810. Epub 2024 Aug 8.
To investigate the effects of β-hydroxybutyrate (BHB) and melatonin on brown adipose tissue (BAT) plasticity in rats fed a high-fat diet (HFD).
We employed a 7-week experimental design for a study on 30 male Sprague-Dawley rats divided into five groups: (1) a control-diet fed group; (2) a high-fat diet (HFD)-fed group; (3) a group that received an HFD and a BHB solution in their drinking water; (4) a group that received an HFD with 10 mg/kg/day melatonin in their drinking water; and (5) a group that received an HFD and were also treated with the combination of BHB and melatonin. Following the treatment period, biochemical indices, gene expression levels of key thermogenic markers (including uncoupling protein 1 [UCP1], PR domain containing 16 [PRDM16], Cidea, fat-specific protein 27 [Fsp27], and metallothionein 1 [MT1]), and stereological assessments of BAT were evaluated.
Treatment with BHB and melatonin significantly boosted blood ketone levels, improved lipid profiles, and reduced weight gain from an HFD. It also downregulated genes linked to WAT, namely, Cidea and Fsp27, and upregulated key BAT markers, including UCP1, PRDM16 and peroxisome proliferator-activated receptor-gamma coactivator-1-alpha. Additionally, the co-treatment increased MT1 receptor expression and enhanced the structural density of BAT.
The combined oral administration of BHB and melatonin successfully prevented the whitening of BAT in obese rats fed an HFD, indicating its potential as a therapeutic strategy for obesity-related BAT dysfunction. The synergistic effects of this treatment underscore the potential of a combined approach to address BAT dysfunction in obesity.
研究β-羟丁酸(BHB)和褪黑素对高脂肪饮食(HFD)喂养大鼠棕色脂肪组织(BAT)可塑性的影响。
我们采用了为期 7 周的实验设计,研究了 30 只雄性 Sprague-Dawley 大鼠,将其分为五组:(1)对照组;(2)HFD 组;(3)HFD 组并饮用 BHB 溶液;(4)HFD 组并饮用 10mg/kg/天褪黑素;(5)HFD 组并联合使用 BHB 和褪黑素。治疗结束后,评估生化指标、关键产热标志物(解偶联蛋白 1 [UCP1]、富含 PR 结构域蛋白 16 [PRDM16]、Cidea、脂肪特异性蛋白 27 [Fsp27]和金属硫蛋白 1 [MT1])的基因表达水平以及 BAT 的体视学评估。
BHB 和褪黑素联合治疗显著提高了血酮水平,改善了血脂谱,减轻了 HFD 引起的体重增加。它还下调了与 WAT 相关的基因,即 Cidea 和 Fsp27,并上调了关键的 BAT 标志物,包括 UCP1、PRDM16 和过氧化物酶体增殖物激活受体-γ共激活因子-1α。此外,联合治疗增加了 MT1 受体的表达并增强了 BAT 的结构密度。
联合口服 BHB 和褪黑素成功防止了 HFD 喂养肥胖大鼠 BAT 的白化,表明其可能是肥胖相关 BAT 功能障碍的一种治疗策略。这种治疗的协同作用突显了联合方法治疗肥胖症中 BAT 功能障碍的潜力。